ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0785

Decreased Peripheral Blood Natural Killer Cell Count in Untreated Juvenile Dermatomyositis Is Associated with Muscle Weakness

Amer Khojah1, Ameera Bukhari2, Chi Trinh3, Gabrielle Morgan4 and Lauren Pachman5, 1Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Department of Microbiology and Immunology, Loyola University Chicago, Chicago, IL, 3Stanley Manne Research Center, Chicago, 4Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 5Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL

Meeting: ACR Convergence 2021

Keywords: CD56, Juvenile Dermatomyosis, Muscle Weakness, Natural Killer Cell

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Title: Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease characterized by muscle and skin inflammation. The Pathophysiology of JDM is complex; it involves both adaptive and innate immune system dysregulation. The increase in type I and type II interferon signature is well documented in JDM patients. IFN-α has been shown to enhance Natural Killer (NK) cell degranulation and inflammatory cytokine production. However, information about how NK cells contribute to the pathophysiology in JDM patients is lacking. This study aims to evaluate the changes in the NK cell count and its correlation with various disease activity markers.

Methods: This IRB-approved retrospective study was conducted at the Ann and Robert H. Lurie Children’s Hospital of Chicago. 135 subjects (76% female, 74% white, 18.5 % Hispanic, 3% black) were included in this study. Clinical and laboratory variables, including age, race, gender, MSA, Disease Activity Scores (DAS skin, muscle, total), nailfold capillary count, neopterin, and muscle enzymes, were obtained from the Lurie Children’s Juvenile Myositis Registry REDCap database. All subjects had flow cytometry (CD3, CD4, CD8, CD16/56, CD19, and HLA-Dr) before receiving treatment for JDM. To identify which NK cell subtype (CD56dim, CD56 bright) is affected in JDM, another flow cytometry was done with CD16 and CD56 on different fluorochromes in a smaller subset of the untreated JDM and control subjects.

Results: 57% of the untreated JDM children had low NK cells. Those with low NK cell count had more active disease with mean DAS-total 11.6 vs 9.6 (p= 0.001), DAS-muscle 5.8 vs 3.9 (p< 0.001), neopterin levels 22.1 vs 15.5 (p=0.003). Muscle enzymes were higher in the NK low groups as following: CPK 2733 vs 474 (p= 0.025), AST 147 vs 54(p= 0.003), LDH 491 vs 348(p= 0.006), Aldolase 23 vs 11(p= 0.013). There was no significant difference in the DAS-skin or nailfold capillary count between NK low group or normal. Among the different MSAs groups, the anti-MJ group has the Lowest mean NK cell count at 105+/- 52, and the anti P155/140 group has the highest level at 196 +/- 161; however, the difference was not statistically significant. Then we examined the NK cell subset in six JDM with low NK cells, three JDM with normal NK, and three healthy controls. CD56 dim NK cell percentage was significantly lower in NK low group than in control (0.55 % vs 4.6 % P< 0.001), whereas CD56 bright percentage did not differ significantly ( 0.45% vs 0.83% P=0.199).

Conclusion: Significant percentage of JDM children have low NK cells before treatment, suggesting that NK cells are likely to be contributing to the disease pathophysiology. Furthermore, JDM subjects with low NK cells show higher disease activity, especially in the muscle weakness and elevated muscle enzymes. Most of the NK cell count reduction is caused by the decreased number of the CD56 dim population, which is more cytotoxic with high perforin expression. Further studies of JDM muscle biopsies are in progress to determine if the CD56 dim NK cell counts are decreased in peripheral blood due to muscle infiltration.


Disclosures: A. Khojah, None; A. Bukhari, None; C. Trinh, None; G. Morgan, None; L. Pachman, None.

To cite this abstract in AMA style:

Khojah A, Bukhari A, Trinh C, Morgan G, Pachman L. Decreased Peripheral Blood Natural Killer Cell Count in Untreated Juvenile Dermatomyositis Is Associated with Muscle Weakness [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/decreased-peripheral-blood-natural-killer-cell-count-in-untreated-juvenile-dermatomyositis-is-associated-with-muscle-weakness/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-peripheral-blood-natural-killer-cell-count-in-untreated-juvenile-dermatomyositis-is-associated-with-muscle-weakness/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology